DDIT3 and diffuse large B-cell lymphoma: While many studies combined targeted drugs with R-CHOP [9–11], Pola-R-CHP was the first to significantly improve progression-free survival (PFS) in patients with DLBCL aged 18–80 with an International Prognostic Index (IPI) 2–5.